English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary   Aim  Use of the glucagon‐like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated the effect of liraglutide on sagittal abdominal diameter, waist circumference, waist‐to‐hip ratio and adiponectin levels in people with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDI).    Materials and methods  In the multicentre, double‐blind, placebo‐controlled MDI‐liraglutide trial, 124 individuals with T2D treated with MDI were randomized to either liraglutide or placebo. Basal values of weight, waist circumference, waist‐to‐hip ratio, sagittal abdominal diameter and adiponectin were compared with measurements at 12 and 24 weeks after randomization.    Results  Baseline‐adjusted mean weight loss was 3.8 ± 2.9 kg greater in liraglutide than placebo‐treated individuals ( p  < 0.0001). Waist circumference was reduced by 2.9 ± 4.3 cm and 0.2 ± 3.6 cm in the liraglutide and placebo groups, respectively, after 24 weeks (baseline‐adjusted mean difference: 2.6 ± 4.0 cm,  p  = 0.0005). Corresponding reductions in sagittal abdominal diameter were 1.1 ± 1.7 cm and 0.0 ± 1.8 cm (baseline‐adjusted mean difference: 1.1 ± 1.7 cm,  p  = 0.0008). Hip circumference was reduced in patients randomized to liraglutide (baseline‐adjusted mean difference between treatment groups: 2.8 ± 3.8 cm,  p  = 0.0001), but there was no significant difference between the groups in either waist‐to‐hip ratio (baseline‐adjusted mean difference: 0.0 ± 0.04 cm,  p  = 0.51) or adiponectin levels (baseline‐adjusted mean difference: 0.8 ± 3.3 mg L −1 ,  p  = 0.17). Lower HbA1c and mean glucose levels measured by masked continuous glucose monitoring at baseline were associated with greater effects of liraglutide on reductions in waist circumference and sagittal abdominal diameter.    Conclusions  In patients with T2D, adding liraglutide to MDI may reduce abdominal and hip obesity to a similar extent, suggesting an effect on both visceral and subcutaneous fat. Liraglutide had greater effects on reducing abdominal obesity in patients with less pronounced long‐term hyperglycaemia but did not affect adiponectin levels.

obesity science and practice

Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5)